Evidence map›Paper›PMID 30975380›Full record

ArticleProstaglandins, leukotrienes, and essential fatty acids2019

Fish oil protects the liver from parenteral nutrition-induced injury via GPR120-mediated PPARγ signaling.

Gillian L Fell, Bennet S Cho, Duy T Dao, Lorenzo Anez-Bustillos, Meredith A Baker, Prathima Nandivada, Amy Pan, Alison A O'Loughlin, Paul D Mitchell, Vania Nose and 2 more

Open access · greenAbstract read
In one paragraph

Article in Prostaglandins, leukotrienes, and essential fatty acids, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Observational
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Gillian L FellVascular Biology Program and Department of Surgery, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, United States.
Bennet S ChoVascular Biology Program and Department of Surgery, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, United States.
Duy T DaoVascular Biology Program and Department of Surgery, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, United States.
Lorenzo Anez-BustillosVascular Biology Program and Department of Surgery, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, United States.
Meredith A BakerVascular Biology Program and Department of Surgery, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, United States.
Prathima NandivadaVascular Biology Program and Department of Surgery, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, United States.
Amy PanVascular Biology Program and Department of Surgery, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, United States.
Alison A O'LoughlinVascular Biology Program and Department of Surgery, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, United States.
Paul D MitchellInstitutional Centers for Clinical and Translational Research, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, United States.
Vania NoseDepartment of Pathology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, United States.
Kathleen M GuraDepartment of Pharmacy, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, United States.
Mark PuderVascular Biology Program and Department of Surgery, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, United States. Electronic address: mark.puder@childrens.harvard.edu.
Boston Children's Hospital · USMassachusetts General Hospital · US

Funding

HARVARD-LONGWOOD RESEARCH TRAINING IN VASCULAR SURGERYT32HL007734 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI FERRAN, CHRISTIANE, LOGERFO, FRANK W · 1993 to 2023
$10.5M
Harvard-Longwood Short-Term Research Training in Vascular SurgeryT35HL110843 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI CHRISTIANE FERRAN, FRANK W LOGERFO · 2013 to 2026
$609k
Generation and use of lipid emulsions to understand mechanisms of and optimally manage parenteral nutrition associated liver diseaseF32DK104525 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI FELL, GILLIAN LYNAPP · 2014 to 2016
$163k
Howard Hughes Medical InstituteNHLBI NIH HHS T32 HL007734NHLBI NIH HHS T35 HL110843NIDDK NIH HHS F32 DK104525NIDDK NIH HHS L40 DK106831
6 · The paper itself

Abstract

Intravenous fish oil lipid emulsions (FOLE) can prevent parenteral nutrition (PN)-induced liver injury in murine models and reverse PN-induced cholestasis in pediatric patients. However, the mechanisms by which fish oil protects the liver are incompletely characterized. Fish oil is rich in omega-3 fatty acids, which are ligands for the G-protein coupled receptor 120 (GPR120), expressed on hepatic Kupffer cells. This study tested the hypothesis that FOLE protects the liver from PN-induced injury through GPR120 signaling. Utilizing a previously described murine model of PN-induced liver injury in which mice develop steatosis in response to an oral parenteral nutrition diet, FOLE was able to preserve normal hepatic architecture in wild type mice, but not in congenic GPR120 knockout (gpr120-/-) mice. To further characterize the requirement of intact GPR120 for FOLE-mediated hepatic protection, gene expression profiles of key regulators of fat metabolism were measured. PPARγ was identified as a gene that is up-regulated by the PN diet and normalized with the addition of FOLE in wild type, but not in gpr120-/- mice. This was confirmed at the protein expression level. A PPARγ expression array further identified CD36 and SCD1, both down-stream effectors of PPARγ, to be up-regulated in PN-fed wild type mice yet normalized upon FOLE administration in wild type but not in gpr120-/- mice. Together, these results suggest that FOLE protects the liver, in part, through activation of GPR120 and the downstream effectors PPARγ and CD36. Identification of key genetic determinants of FOLE-mediated hepatic protection may provide targets for small molecule-based hepatic protection strategies.

Indexed as

AnimalsCD36 AntigensChemical and Drug Induced Liver InjuryDisease Models, AnimalFat Emulsions, IntravenousFatty LiverFish OilsGene Knockout TechniquesMiceMice, Inbred C57BLMice, KnockoutParenteral NutritionPPAR gammaProtective AgentsReceptors, G-Protein-CoupledSignal TransductionCD36 AntigensCd36 protein, mouseFat Emulsions, IntravenousFFAR4 protein, mouseFish OilsPPAR gammaPparg protein, mouseProtective AgentsReceptors, G-Protein-CoupledScd1 protein, mouseStearoyl-CoA DesaturaseFish oilGPR120Intestinal failure-associated liver diseaseLipid emulsionsNon-alcoholic fatty liver diseaseOmega-3 fatty acidsPeroxisome proliferator-activated receptor-gamma

Identifiers

PMID30975380
PMCPMC6642797
OpenAlexW2919067060

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.